| Literature DB >> 35625200 |
Duangdao Sudatip1,2, Surapee Tiengrim3, Kittipong Chasiri4, Anamika Kritiyakan5, Wantanee Phanprasit2, Serge Morand4, Visanu Thamlikitkul6.
Abstract
Integrated surveillance of antimicrobial resistance (AMR) using the One Health approach that includes humans, animals, food, and the environment has been recommended by responsible international organizations. The objective of this study was to determine the prevalence of AMR phenotypes in Escherichia coli and Klebsiella species isolated from humans, pigs, chickens, and wild rodents in five communities in northern Thailand. Rectal swabs from 269 pigs and 318 chickens; intestinal contents of 196 wild rodents; and stool samples from 69 pig farmers, 155 chicken farmers, and 61 non-farmers were cultured for E. coli and Klebsiella species, which were then tested for resistance to ceftriaxone, colistin, and meropenem. The prevalence of ceftriaxone-resistant E. coli and Klebsiella species in pigs, chickens, rodents, pig farmers, chicken farmers, and non-farmers was 64.3%, 12.9%, 4.1%, 55.1%, 38.7%, and 36.1%, respectively. Colistin resistance in pigs, chickens, rodents, pig farmers, chicken farmers, and non-farmers was 41.3%, 9.8%, 4.6%, 34.8%, 31.6%, and 24.6%, respectively. Meropenem resistance was not detected. The observed high prevalence of AMR, especially colistin resistance, in study food animals/humans is worrisome. Further studies to identify factors that contribute to AMR, strengthened reinforcement of existing regulations on antimicrobial use, and more appropriate interventions to minimize AMR in communities are urgently needed.Entities:
Keywords: One Health surveillance; Thailand; antimicrobial resistance phenotype; community
Year: 2022 PMID: 35625200 PMCID: PMC9137618 DOI: 10.3390/antibiotics11050556
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Prevalence of ceftriaxone, colistin, and meropenem resistance in Escherichia coli and Klebsiella species isolated from samples collected from various animal and human sources.
| Source of Samples | Ceftriaxone Resistance a | Colistin Resistance b | Meropenem Resistance c |
|---|---|---|---|
| Pig ( | 173 (64.3%) | 111 (41.3%) | 0 (0.0%) |
| Chicken ( | 41 (12.9%) | 31 (9.8%) | 0 (0.0%) |
| Wild rodent ( | 8 (4.1%) | 9 (4.6%) | 0 (0.0%) |
| Pig farmer ( | 38 (55.1%) | 24 (34.8%) | 0 (0.0%) |
| Chicken farmer ( | 60 (38.7%) | 49 (31.6%) | 0 (0.0%) |
| Non-farmer ( | 22 (36.1%) | 15 (24.6%) | 0 (0.0%) |
| Total ( | 342 (32.0%) | 239 (22.4%) | 0 (0.0%) |
a Minimum inhibitory concentration (MIC) of ceftriaxone ≥ 4 μg/mL; b MIC of colistin ≥ 4 μg/mL; c MIC of meropenem ≥ 4 μg/mL.
Prevalence of ceftriaxone, colistin, and meropenem resistance in Escherichia coli isolated from samples collected from various animal and human sources.
| Source of Samples | Ceftriaxone Resistance a | Colistin Resistance b | Meropenem Resistance c |
|---|---|---|---|
| Pig ( | 168 (62.5%) | 109 (40.5%) | 0 (0.0%) |
| Chicken ( | 36 (11.3%) | 29 (9.1%) | 0 (0.0%) |
| Wild rodent ( | 8 (4.1%) | 9 (4.6%) | 0 (0.0%) |
| Pig farmer ( | 37 (53.6%) | 23 (33.3%) | 0 (0.0%) |
| Chicken farmer ( | 58 (37.4%) | 48 (31.0%) | 0 (0.0%) |
| Non-farmer ( | 19 (31.2%) | 14 (23.0%) | 0 (0.0%) |
| Total ( | 326 (30.5%) | 232 (21.7%) | 0 (0.0%) |
a Minimum inhibitory concentration (MIC) of ceftriaxone ≥ 4 μg/mL; b MIC of colistin ≥ 4 μg/mL; c MIC of meropenem ≥ 4 μg/mL.
Prevalence of ceftriaxone, colistin, and meropenem resistance in Klebsiella species isolated from samples collected from various animal and human sources.
| Source of Samples | Ceftriaxone Resistance a | Colistin Resistance b | Meropenem Resistance c |
|---|---|---|---|
| Pig ( | 5 (1.9%) | 2 (0.7%) | 0 (0.0%) |
| Chicken ( | 5 (1.6%) | 2 (0.6%) | 0 (0.0%) |
| Wild rodent ( | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Pig farmer ( | 1 (1.5%) | 1 (1.5%) | 0 (0.0%) |
| Chicken farmer ( | 2 (1.3%) | 1 (0.6%) | 0 (0.0%) |
| Non-farmer ( | 3 (4.9%) | 1 (1.6%) | 0 (0.0%) |
| Total ( | 16 (1.5%) | 7 (0.7%) | 0 (0.0%) |
a Minimum inhibitory concentration (MIC) of ceftriaxone ≥ 4 μg/mL; b MIC of colistin ≥ 4 μg/mL; c MIC of meropenem ≥ 4 μg/mL.